Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Breast Cancer
Advancements in Targeted Therapy and Immunotherapy for Human Breast Cancer
Read More
Breast Cancer
Latest Updates on Targeted Therapy in HR-Positive and HER2-Negative Breast Cancer
Read More
Breast Cancer
,
CDK4/6 Inhibitors
Resistance Mechanisms to CDK4/6 Blockade in Advanced HR-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities
Read More
Breast Cancer
Olaparib Monotherapy in Triple-Negative Breast Cancer
Read More
Breast Cancer
2021 Breast Cancer Year in Review Introduction
Read More
Breast Cancer
Dalpiciclib plus Fulvestrant in HR-Positive and HER2-Negative Advanced Breast Cancer
Read More
Breast Cancer
Palbociclib in Combination with Aromatase Inhibitors in Elderly Patients with Estrogen Receptor–Positive and HER2-Negative Advanced Breast Cancer
Read More
Breast Cancer
Olaparib as Adjuvant Therapy in Patients with BRCA1 or BRCA2 Mutation–Positive Breast Cancer
Read More
Breast Cancer
Olaparib’s OlympiA Trial Crossed the Superiority Limit for Invasive Disease-Free Survival versus Placebo
Read More
Breast Cancer
Real-World Tumor Response of Palbociclib plus Letrozole versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 28
